Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | PNMT | P11086 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27984426 | 1.00 | CYP11B1 (0.43) | CYP11B1CYP11B2PNMTDRD2DRD3 | |
| SCHEMBL28331918 | 0.86 | TRPA1 (0.49) | CYP11B1CYP11B2PNMTDRD2DRD3 | |
| SCHEMBL9573469 | 0.72 | DRD2 (0.37) | DRD2DRD3TRPA1 | |
| SCHEMBL29769963 | 0.72 | CASP1 (0.37) | DRD3 | |
| SCHEMBL9573205 | 0.72 | HTR2A (0.38) | CYP11B1CYP11B2PNMTKDM1ACYP19A1 | |
| SCHEMBL17288494 | 0.72 | PNMT (0.46) | CYP11B1CYP11B2PNMTDRD2DRD3 | |
| SCHEMBL30025550 | 0.72 | ADRA2A (0.34) | CYP1A2 | |
| SCHEMBL28191945 | 0.72 | — | — | |
| SCHEMBL9573203 | 0.72 | CYP19A1 (0.33) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL7938077 | 0.72 | ADRA2A (0.34) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CYP11B1 2896/4885CYP11B2 2659/4885PNMT 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.